Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHayley, Amie C-
dc.contributor.authorGreen, Maja-
dc.contributor.authorDowney, Luke A-
dc.contributor.authorStough, Con K K-
dc.contributor.authorKeane, Michael-
dc.contributor.authorShiferaw, Brook-
dc.contributor.authorKostakis, Panagiota-
dc.contributor.authorShehabi, Yahya-
dc.identifier.citationProgress in neuro-psychopharmacology & biological psychiatry 2018; 86: 83-88-
dc.description.abstractKetamine hydrochloride elicits potent psychotomimetic and neurobehavioural effects which make it incompatible with driving; however, the direct effect on driving performance is yet to be assessed. Using an open label, within-subjects protocol, 15 males and 5 females (mean age = 30.8 years) were administered three fixed, stepwise increasing sub-anaesthetic doses of intravenous (IV) ketamine solution [(i) 8 mg/h IV infusion plus 30 mg bolus, (ii) 12 mg/h IV infusion and (iii) 20 mg/h infusion]. Whole blood ketamine and norketamine concentrations were determined at each treatment step and at 2 h post-infusion. Driving performance was assessed at baseline, at each treatment step and at 2 h post-treatment using a validated computerised driving simulator. Standard Deviation of Lateral Position (SDLP) and Steering Variability (SV) were assessed. Linear Fixed Effect Modelling indicated a main effect for time (dose) for SDLP (F[4,72] = 33.22, p < 0.0001) and SV (F[4,72] = 4.65, p < 0.002). Post-hoc analyses revealed significant differences from baseline at each treatment step for SDLP (all p < 0.001), and for 12 mg/h treatment step for SV (p = 0.049). Post-treatment driving performance returned to baseline levels. Weak positive linear associations were observed between SDLP and whole blood ketamine concentrations (R2 = 0.11, β = 29.96, p = 0.001) and norketamine (R2 = 0.09, β = 28.87, p = 0.003). These findings suggest that even under highly controlled conditions, ketamine intoxication significantly alters simulated driving performance. At the highest dose, ketamine produced changes to SDLP considered incompatible with safe driving, highlighting how ketamine consumption may translate to an increased risk of road trauma.-
dc.titleThe acute and residual effects of escalating, analgesic-range doses of ketamine on driving performance: A simulator study.-
dc.typeJournal Article-
dc.identifier.journaltitleProgress in neuro-psychopharmacology & biological psychiatry-
dc.identifier.affiliationCentre for Human Psychopharmacology, Swinburne University of Technology, Hawthorn, Victoria, Australia-
dc.identifier.affiliationProgram of Critical Care and Perioperative Medicine, School of Clinical Sciences Monash Health, Victoria, Australia-
dc.identifier.affiliationDepartment of Oncology, Monash Health Translation Precinct, Monash University, Clayton, Victoria, Australia-
dc.identifier.affiliationInstitute for Breathing and Sleep, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.affiliationForensic Science South Australia (FSSA), Adelaide, South Australia, Australia-
dc.type.austinJournal Article-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.openairecristype for Breathing and Sleep-
Appears in Collections:Journal articles
Show simple item record

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.